𝕏
Latest

Author

Tom Harland

Markets reporter

Tom Harland reports on pharma and biotech earnings, guidance, share moves and IPOs for PharmaWire.

Latest from Tom Harland

Markets

Four Pharma Franchises Stumble Despite Blockbuster Status

A drug generating more than $1bn in quarterly sales might ordinarily be cause for celebration. But when Alnylam Pharmaceuticals (ALNY) reported $1.01bn in second-quarter Amvuttra revenues — fractionally below published consensus estimates…